Paradoxical Reactions of Remimazolam in Pediatric Painless Gastrointestinal Endoscopy
NCT ID: NCT06419543
Last Updated: 2024-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
333 participants
INTERVENTIONAL
2024-05-20
2024-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Remiazolam Combined With Esketamine in Painless Bidirectional Endoscopy in Children
NCT05686863
Effect of Esketamine on 95% Induction Dose of Remimazolam
NCT06303037
Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy
NCT00869440
Comparison Between Remimazolam Tosilate and Midazolam in Elderly Patients Undergoing Gastrointestinal Endoscopy
NCT04656964
Remimazolam Improves the Safety in Elderly Patients Undergoing Gastrointestinal Endoscopy
NCT05406102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group R1
The first induction dose of remimazolam is 0.1mg/kg.
Remimazolam
Observe the incidence of paradoxical reactions after the first induction.
Group R2
The first induction dose of remimazolam is 0.2mg/kg.
Remimazolam
Observe the incidence of paradoxical reactions after the first induction.
Group R3
The first induction dose of remimazolam is 0.3mg/kg.
Remimazolam
Observe the incidence of paradoxical reactions after the first induction.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Remimazolam
Observe the incidence of paradoxical reactions after the first induction.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA I-II level
* Sign an informed consent form
Exclusion Criteria
* Severe malnutrition or severe obesity
* High risk of stomach fullness and reflux aspiration
* Allergic to benzodiazepines and opioids
* Those who have taken sedative, analgesic, or antidepressant drugs within 24hours
* Severe sleep apnea
* Abnormal liver and kidney function
* Recently participated in other clinical studies
1 Year
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tongji Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
aijun xu
Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
aihua Du, Dr.
Role: STUDY_CHAIR
Tongji Hospita
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tongji hospital
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRPG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.